Inventor · disambiguated record
Lan Jiang
Also filed as: JIANG LAN
66 granted patents·23 pending applications·543 citations·filing 2001–2024
99Inventor score
Files withGILEAD SCIENCES INC27THERAVANCE BIOPHARMA R&D IP LLC17PLIANT THERAPEUTICS INC12THERAVANCE INC12LONG DANIEL D8
Top patents by PatentIndex Score
89 records- 0198US10526330B2JAK kinase inhibitor compounds for treatment of respiratory diseaseTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2018·Granted Jan 7, 2020·15 cites·13 claims
- 0298US10100049B2JAK kinase inhibitor compounds for treatment of respiratory diseaseTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2016·Granted Oct 16, 2018·28 cites·17 claims
- 0397US11613546B2Substituted pyridotriazine compounds and uses thereofGILEAD SCIENCES INC·Filed 2022·Granted Mar 28, 2023·9 cites·44 claims
- 0497US11548902B1Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical useGILEAD SCIENCES INC·Filed 2021·Granted Jan 10, 2023·7 cites·60 claims
- 0597US11084832B2Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical useGILEAD SCIENCES INC·Filed 2020·Granted Aug 10, 2021·25 cites·47 claims
- 0697US10988451B2MCL-1 inhibitorsGILEAD SCIENCES INC·Filed 2020·Granted Apr 27, 2021·10 cites·21 claims
- 0797US10696672B2Amino acid compounds and methods of usePLIANT THERAPEUTICS INC·Filed 2017·Granted Jun 30, 2020·21 cites·34 claims
- 0897US7622508B28-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonistsTHERAVANCE INC·Filed 2007·Granted Nov 24, 2009·39 cites·19 claims
- 0996US11897892B2Substituted pyridotriazine compounds and uses thereofGILEAD SCIENCES INC·Filed 2023·Granted Feb 13, 2024·6 cites·35 claims
- 1096US11643400B2MCL-1 inhibitorsGILEAD SCIENCES INC·Filed 2021·Granted May 9, 2023·4 cites·20 claims
- 1196US11634418B2Amino acid compounds and methods of usePLIANT THERAPEUTICS INC·Filed 2020·Granted Apr 25, 2023·5 cites·41 claims
- 1296US10793564B2Amino acid compounds and methods of usePLIANT THERAPEUTICS INC·Filed 2019·Granted Oct 6, 2020·25 cites·69 claims
- 1396US10703733B2MCL-1 inhibitorsGILEAD SCIENCES INC·Filed 2019·Granted Jul 7, 2020·12 cites·27 claims
- 1496US10493077B2Fused imidazo-piperidine JAK inhibitor compoundTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2018·Granted Dec 3, 2019·14 cites·19 claims
- 1595US12024528B2Bridged tricyclic carbamoylpyridone compounds and uses thereofGILEAD SCIENCES INC·Filed 2023·Granted Jul 2, 2024·6 cites·28 claims
- 1695US11697652B2Tetracyclic compounds and uses thereofGILEAD SCIENCES INC·Filed 2021·Granted Jul 11, 2023·7 cites·52 claims
- 1795US11560376B2Amino acid compounds and methods of usePLIANT THERAPEUTICS INC·Filed 2020·Granted Jan 24, 2023·6 cites·79 claims
- 1895US10604520B2N-acyl amino acid compounds and methods of usePLIANT THERAPEUTICS INC·Filed 2017·Granted Mar 31, 2020·20 cites·52 claims
- 1994US9663509B28-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonistsLONG DANIEL D·Filed 2015·Granted May 30, 2017·10 cites·2 claims
- 2094US8263618B28-azabicyclo[3.2.1]octane compounds as MU opioid receptor antagonistsLONG DANIEL D·Filed 2009·Granted Sep 11, 2012·18 cites·15 claims
- 2194US7759363B2Benzimidazole-carboxamide compounds as 5-HT4, receptor agonistsTHERAVANCE INC·Filed 2006·Granted Jul 20, 2010·18 cites·18 claims
- 2294US7691878B2Heteroarylalkyl-8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonistsTHERAVANCE INC·Filed 2008·Granted Apr 6, 2010·13 cites·19 claims
- 2394US7396933B2Quinolinone-carboxamide compoundsTHERAVANCE INC·Filed 2005·Granted Jul 8, 2008·28 cites·13 claims
- 2493US12187734B2Substituted pyridotriazine compounds and uses thereofGILEAD SCIENCES INC·Filed 2023·Granted Jan 7, 2025·1 cites·27 claims
- 2593US12054496B2Bridged tricyclic carbamoylpyridone compounds and uses thereofGILEAD SCIENCES INC·Filed 2023·Granted Aug 6, 2024·2 cites·30 claims
- 2693US11299492B2JAK kinase inhibitor compounds for treatment of respiratory diseaseTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2021·Granted Apr 12, 2022·2 cites·13 claims
- 2793US8664242B28-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonistsLONG DANIEL D·Filed 2012·Granted Mar 4, 2014·13 cites·6 claims
- 2893US7399862B25-HT4 receptor agonist compoundsTHERAVANCE INC·Filed 2005·Granted Jul 15, 2008·26 cites·12 claims
- 2992US11673887B2N-acyl amino acid compounds and methods of usePLIANT THERAPEUTICS INC·Filed 2020·Granted Jun 13, 2023·3 cites·68 claims
- 3092US11667652B2MCL1 inhibitorsGILEAD SCIENCES INC·Filed 2020·Granted Jun 6, 2023·2 cites·15 claims
- 3192US9206172B28-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonistsLONG DANIEL D·Filed 2014·Granted Dec 8, 2015·10 cites·2 claims
- 3292US8927573B28-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonistsLONG DANIEL D·Filed 2014·Granted Jan 6, 2015·10 cites·15 claims
- 3392US8377964B2Benzimidazole-carboxamide compounds as 5-HT4 receptor agonistsTHERAVANCE INC·Filed 2010·Granted Feb 19, 2013·10 cites·17 claims
- 3492US7902220B28-azabicyclo[3.2.1]octyl-2-hydroxybenzamide compounds as mu opioid receptor antagonistsTHERAVANCE INC·Filed 2008·Granted Mar 8, 2011·14 cites·14 claims
- 3591US10745394B28-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonistsTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2019·Granted Aug 18, 2020·2 cites·11 claims
- 3691US10081626B28-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonistsTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2017·Granted Sep 25, 2018·5 cites·7 claims
- 3790US7534889B25-HT4 receptor agonist compoundsTHERAVANCE INC·Filed 2008·Granted May 19, 2009·13 cites·16 claims
- 3889US10377751B28-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonistsTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2018·Granted Aug 13, 2019·3 cites·2 claims
- 3988US11548887B28-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonistsTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2020·Granted Jan 10, 2023·1 cites·16 claims
- 4088US9428489B2Benzimidazole-carboxamide compounds as 5-HT4 receptor agonistsMCKINNELL ROBERT MURRAY·Filed 2014·Granted Aug 30, 2016·6 cites·8 claims
- 4188US7498442B2Quinolinone-carboxamide compoundsTHERAVANCE INC·Filed 2008·Granted Mar 3, 2009·10 cites·10 claims
- 4288US7446114B2Quinolinone compounds as 5-HT4 receptor agonistsTHERAVANCE INC·Filed 2006·Granted Nov 4, 2008·10 cites·15 claims
- 4387US2025154116A1Mcl-1 inhibitorsGILEAD SCIENCES INC·Filed 2024·Application pending·0 cites
- 4486US8481563B28-azabicyclo[3.2.1]octyl-2-hydroxybenzamide compounds as mu opioid receptor antagonistsSAITO DAISUKE ROLAND·Filed 2011·Granted Jul 9, 2013·7 cites·19 claims
- 4586US7902221B2Amidoalkyl-8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonistsTHERAVANCE INC·Filed 2008·Granted Mar 8, 2011·10 cites·14 claims
- 4685US7875629B2Quinolinone compounds as 5-HT4 receptor agonistsTHERAVANCE INC·Filed 2008·Granted Jan 25, 2011·6 cites·11 claims
- 4785US2023183232A18-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonistsTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2022·Application pending·0 cites
- 4885US2025188089A1Substituted pyridotriazine compounds and uses thereofGILEAD SCIENCES INC·Filed 2024·Application pending·0 cites
- 4984US8921372B2Inhibitors of hepatitis C virusMCKINNELL ROBERT MURRAY·Filed 2011·Granted Dec 30, 2014·8 cites·18 claims
- 5084US8518966B2Amidoalkyl-8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonistsLONG DANIEL D·Filed 2011·Granted Aug 27, 2013·6 cites·19 claims
Showing the top 50 of 89 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Lan Jiang files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →